Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

IMPORTANCE: The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, the long-term efficacy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Diamond, Eli L., Subbiah, Vivek, Lockhart, A. Craig, Blay, Jean-Yves, Puzanov, Igor, Chau, Ian, Raje, Noopur S., Wolf, Jurgen, Erinjeri, Joseph P., Torrisi, Jean, Lacouture, Mario, Elez, Elena, Martínez-Valle, Ferran, Durham, Benjamin, Arcila, Maria E., Ulaner, Gary, Abdel-Wahab, Omar, Pitcher, Bethany, Makrutzki, Martina, Riehl, Todd, Baselga, José, Hyman, David M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2017
Soggetti:
Brief Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844839/
https://ncbi.nlm.nih.gov/pubmed/29188284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5029
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi